To determine the effect of our compound (BMS-919373) on electrical activity of the heart using pacemakers.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
7
Local Institution
Austin, Texas, United States
The University Of Calgary
Calgary, Alberta, Canada
University Of Ottawa Heart Institute
Ottawa, Ontario, Canada
Local Institution - 0001
Toronto, Ontario, Canada
The effect of BMS-919373 on Atrial effective refractory period (AERP) in subjects with a dual chamber pacemaker
Time frame: At 0.5, 1, 2, and 4 hours following study drug administration
The safety assessments will be based on Adverse event reports, vital sign measurements, Electrocardiogram (ECGs), physical examinations and clinical laboratory tests
Time frame: At 1, 2, and 4 hours following study drug administration
Safety assessments based on Ventricular Effective Refractory Period (VERP) and change from baseline
Time frame: At 2 hour following study drug administration
Safety assessments based on Atrioventricular interval (AVI) and change from baseline
Time frame: At 1, 2, and 4 hours following study drug administration
Safety assessments based on Wenckebach cycle length (WCL) and change from baseline
Time frame: At 1, 2, and 4 hours following study drug administration
Safety assessments based on Intra-atrial conduction time (IACT) and change from baseline
Time frame: At 1, 2, and 4 hours following study drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Local Institution - 0002
Montreal, Quebec, Canada
Local Institution
Montreal, Quebec, Canada